Home > Healthcare > Pharmaceuticals > Finished Drug Form > Anthrax Treatment Market

Anthrax Treatment Market Share

Report ID: GMI9700
Published Date: May 2024
Report Format: PDF

Download Free Sample

Anthrax Treatment Market Share

The anthrax treatment industry is highly competitive characterized by the presence of several key players, including pharmaceutical companies and biotechnology firms. The competitive landscape is shaped by factors such as technological advancements, regulatory requirements, government funding, partnerships, and market dynamics. Collaboration between industry players, research institutions, and government agencies is crucial for advancing the development and availability of effective anthrax treatments.

Anthrax Treatment Market Companies

Prominent players operating in the anthrax treatment industry include:

Alembic Pharmaceuticals Limited
Almirall, LLC
Bayer AG
Emergent BioSolutions
GlaxoSmithKline plc
GC Biopharma, corp.
Integrated Bio Therapeutics Inc.
Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
Paratek Pharmaceuticals, Inc.
Pfizer Inc.
Porton Biopharma
Sanofi SA
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Industry size for anthrax treatment was worth USD 364.4 million in 2023 and is projected to expand at 7.9% CAGR from 2024 to 2032, due to the advancements in biotechnology and drug development.

The inhalation anthrax type segment in the anthrax treatment industry accounted for 44.5% share in 2023 and is estimated to depict notable CAGR between 2024 and 2032, as it is a highly recognized and the most severe form of the disease.

The antibiotics drug class segment in the anthrax treatment industry recorded USD 227.4 million in 2023, due to its pivotal role as the primary treatment modality, backed by proven efficacy, safety, and broad-spectrum activity against Bacillus anthracis.

North America market size recorded USD 141.7 million in revenue in 2023 and is projected to grow at 7.8% CAGR between 2024 and 2032, owing to the presence of significant livestock population, particularly cattle, which is highly susceptible to anthrax leading to increased risk of anthrax transmission to humans.